Flex Pharma Announces FLX-787 as Clinical Drug Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
Flex Pharma (FLKS) Selects FLX-787 as Clinical Drug Candidate
November 10, 2015 4:24 PM ESTFlex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced today at its Investor Day in New York City that the Company has selected FLX-787 as its clinical candidate for studies outside the United States. FLX-787 is a purified, GMP-synthesized single agent consisting of one highly selective and specific transient receptor potential (TRP) ion channel agonist.
After testing the most potent TRPA1 and TRPV1 agonists and demonstrating enhanced efficacy... More
